The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

Novel therapies are urgently needed to prevent and treat tyrosine kinase inhibitor resistance in chronic myeloid leukaemia (CML). MLN8237 is a novel Aurora A kinase inhibitor under investigation in multiple phase I and II studies. Here we report that MLN8237 possessed equipotent activity against Ba/...

Full description

Saved in:
Bibliographic Details
Published in:J Cell Mol Med
Main Authors: Kelly, Kevin R, Ecsedy, Jeffrey, Medina, Ernest, Mahalingam, Devalingam, Padmanabhan, Swaminathan, Nawrocki, Steffan T, Giles, Francis J, Carew, Jennifer S
Format: Artigo
Language:Inglês
Published: Blackwell Publishing Ltd 2011
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394217/
https://ncbi.nlm.nih.gov/pubmed/21091633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1582-4934.2010.01218.x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items